KR102351363B1 - Composition for Anti-Allergy Using Solubilized Mastic Gum or an Extract of Lindera glauca - Google Patents

Abstract

The present invention provides a composition for anti-allergy using water-soluble mastic gum or an extract of Lindera glauca which has degranulation inhibitory activity when treated with a mast cell line rat basophilic leukemia (RBL-2H3) activated with IgE and antigen (DNP-BSA).

Description

Composition for Anti-Allergy Using Solubilized Mastic Gum or an Extract of Lindera glauca

The present invention relates to a composition for anti-allergy using water- soluble mastic gum or an extract of E. glauca.

Allergy is a compound word created by combining the Greek words 'allos' meaning 'change' and 'ergo' meaning 'action'. As the etymology is like this, an allergy refers to a hypersensitivity reaction such as urticaria, itchiness, runny nose, and cough in a specific person due to an abnormality in innate or acquired immune function to an allergen, a substance that does not show any reaction to ordinary people. Typical allergens include pollen, drugs, vegetable fibers, bacteria, mold, house dust mites, food (eg, egg albumin, milk protein, peanuts), hair dye, and chemicals. Due to an increase in substances, environmental pollution, a decrease in immune function due to stress, and changes in diet, these allergic diseases are increasing worldwide.

Allergic reactions are classified into five types: type I anaphylaxis type, type II cytolytic type, type III immune complex type, type IV cell mediated type, and type V stimulatory hypersensitivity type, most of which belong to type I, and generally Allergic reaction is used in the same sense as type I (Roitt I, Brostoff J, Male D. Immunology 6th eds. USA. Mosby. 2001:323-383).

Representative allergic diseases include atopic dermatitis, bronchial asthma, allergic rhinitis, allergic keratitis, and skin urticaria. In these allergic diseases, mast cells are known as important effector cells (Wills-Karp M., et al., Science, 282:2258-61, 1998; Grunig G., et al., Science, 282:2261-2263, 1998). Mast cells are cells that are widely distributed in organs throughout the body, such as the skin, respiratory system, lymphatic vessels, mucous membranes of the gastrointestinal tract, blood vessels, and brain (Ishizaka t., et al. J. Immunol. 119:1589, 1997).

Allergic reactions are induced through activation of intracellular signaling pathways when an allergen binds to IgE, which is bound to the IgE high affinity receptor (FcεRI) on the surface of mast cells. Specifically, when an allergen invades a living body, T-helper cells and B cells are sequentially activated to generate IgE. Allergens that invade the living body are recognized by antigen-presenting cells, which differentiate Th0 (T helper cell type 0) into Th2 cells by presenting the allergen. The differentiated Th2 cells secrete cytokines such as IL-4, IL-5, and IL-13, which promote the development of acid leukocytes in the bone marrow and induce acid leukocytes to the inflamed tissue, as well as B cells. It induces the production of IgE and IgG1.

The generated IgE binds to the high-affinity IgE receptor (FcRIα) of the mast cell membrane, and when allergens such as mites and pollen bind to it and cross-link it, the receptor (FcRIα) aggregates. By crosslinking and aggregation of the receptor (FcRIα), mast cells are activated and the ^{concentration of calcium ions (Ca ++} ) in the cytoplasm, etc. rises. The increase in calcium ion concentration acts on several types of intracellular regulators such as cholesterol in the cell membrane and the cytoskeletal system, and moves the granules to the cell membrane, and at the same time, degranulates through vacuolization of granules, fusion of granules, and fusion of granules and cell membranes. causes When degranulation occurs, preformed mediators stored in mast cells, such as histamine, are released and, at the same time, newly synthesized prostaglandin and leukotriene are secreted together. Chemical transmitters liberated by degranulation include histamine, serotonin, and leukotriene, which have actions such as vasodilation, enhancement of vascular permeability, contraction or hypersecretion of bronchial smooth muscle, and NCF acting as a chemotactic factor of inflammatory cells such as eosinophils and neutrophils. , ECF, PAF, etc. cause an allergic reaction (Ennis M, et al., Br J Pharmacol 70:329-334, 1980; Metcalfe DD, et al., Crit Rev Immunol 3:23-74, 1981; Miyajima I, et al., J Clin Invest 99:901-914, 1997; Church MK, et al., J Allergy Clin Immunol 99:155-160, 1997; Jones DA, et al., J Biol Chem 268:9049- 9054, 1993).

Cyclooxygenase (COX) and lipoxygenase (LO) are known to catalyze a part of the process of producing prostaglandins and leukotrienes, which are allergy symptom-causing substances, from arachidonic acid (Sekiya K , et al., Biochem Biophys Acta 713:68-72, 1982)

Therefore, substances that inhibit the activation of mast cells, inhibit the release of histamine, or inhibit the synthesis of prostaglandins and leukotrienes can be effective therapeutic drugs for allergies.

Currently, anti-allergic drugs include antihistamines (alkylamines, desloratadine, etc.), mast cell stabilizers (cromoglycate, etc.), leukotriene blockers (montelukast, etc.), and anti-IgE antibody (Omalizumab). However, in most cases, the effect of these drugs is temporary and the side effects are severe in many cases. Therefore, it can be said that there is still a need to develop a new substance that has a preventive and ameliorating effect on allergic diseases, few side effects and a continuous effect, and in particular, natural products have the advantage of relatively low toxicity.

The present invention discloses anti-allergic activity of water-soluble mastic gum or E. E. tree extract.

An object of the present invention is to provide a composition for anti-allergy using water-soluble mastic gum or E. E. tree extract.

Other objects or specific objects of the present invention will be set forth below.

As confirmed in the Examples and Experimental Examples below, the present invention is to be treated with mast cell line RBL-2H3 (rat basophilic leukemia) activated with IgE and antigen (DNP-BSA) in which water-soluble mastic gum or E. E. tree extract is treated. It was completed by confirming that it inhibits degranulation when The mast cell line, RBL-2H3, has an IgE antibody receptor (FcεRI) on its surface, and when activated with IgE and antigen, degranulation is induced to secrete mediators of allergic reactions such as histamine. Beta- Hexosaminidase (β-hexosaminidase) is known as an indicator of degranulation (Planta Med 64:577-578, 1998)

Considering the above, the present invention can be understood as an anti-allergy composition or antihistamine composition comprising water-soluble mastic gum, E. E. tree extract, or a mixture thereof as an active ingredient.

As used herein, "water-soluble mastic gum" refers to a suspension (suspension) in which mastic gum is made into fine particles (average particle diameter in the range of 1 to 999 μm) to nanoparticles (average particle diameter in the range of 1 to 999 nm) and suspended in water as a solvent ( In other words, it means that the dispersed state is maintained without agglomeration or precipitation in water, which is a solvent). Such water-soluble mastic gum can be obtained by grinding mastic gum into fine particles or nanoparticles, adding water thereto, stirring, and mixing, in particular, grinding mastic gum into fine particles, adding water thereto, mixing, and It may be preferable to grind the mixture (or liquid mixture) to obtain nanoparticles of mastic gum particles in the mixture. In this case, in order to stabilize the dispersed particles and prevent their agglomeration and precipitation, suspending agents may be added in an appropriate amount before and after mixing with water and before and after grinding the fine particles or nanoparticles of mastic gum. Any suspending agent known in the art may be used, for example, gum arabic, tragacanth gum, agar, karaya gum, locust bean gum, guar gum ( guar gum), xanthan gum, ghatti gum, water-soluble polymers such as pectin, cyclodextrin, glycerin or fatty acid ester derivatives thereof, methylcellulose or hydroxymethylcellulose Modified cellulose, various surfactants, etc. may be used. These suspending agents may be used alone or in combination of two or more, and may be used in an appropriate amount for suspending, specifically, in an amount of 20 to 200 parts by weight based on 100 weight of mastic gum. For more specific information on the preparation of water-soluble mastic gum, refer to the examples below, or Korean Patent Registration No. 10, whose title is "Method for preparing an aqueous solution of mastic gum with increased dispersing and water-soluble power through nano-particleization" Reference may be made to the method disclosed in -1865712 and the like. Here, mastic gum refers to the resin (reisn) obtained from the mastic tree (Pistacia lentiscus).

In addition, in the present specification, "E. E. tree extract" refers to the extraction target E. E. leaf, stem, above-ground part, rhizome, root, underground part, outpost, or a mixture thereof with water, a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, butanol, etc.) , methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or these It means an extract obtained by leaching using a mixed solvent of In consideration of this, any method such as chilling, reflux, warming, ultrasonic radiation, or supercritical extraction may be applied. In the case of the fractionated extract, a fraction obtained by suspending the extract in a specific solvent and mixing and standing still with a solvent having a different polarity, and adsorbing the crude extract to a column filled with silica gel, etc. It is meant to include the fraction obtained as a mobile phase. In addition, the meaning of the extract includes a concentrated liquid extract or solid extract from which the extraction solvent is removed by methods such as freeze drying, vacuum drying, hot air drying, spray drying, and the like. Preferably, an extract obtained by using water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof as an extraction solvent, more preferably a mixed solvent of water and an alcohol having 1 to 4 carbon atoms as an extraction solvent, especially a mixed solvent of ethanol and water means an extract obtained using

In addition, as used herein, the term "active ingredient" refers to a component that alone exhibits the desired activity or can exhibit activity together with a carrier that has no activity by itself.

In addition, in the present specification, "anti-allergy" is meant to include improvement (relief of symptoms), treatment, and prevention (suppression or delay of onset) of allergic diseases as defined below.

In addition, in the present specification, "allergic disease" means a pathological symptom caused by an allergic reaction mediated by the activation of mast cells, such as degranulation of mast cells, and such allergic diseases include atopic dermatitis, asthma. , allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, allergic keratitis, and the like.

The anti-allergic composition of the present invention may contain the active ingredient in any amount (effective amount) as long as it can exhibit the amelioration activity of the intended treatment according to the use, formulation, purpose of formulation, etc. It will be determined within the range of 0.001% to 15% by weight based on the total weight of the composition. Herein, the term "effective amount" refers to the intended medical and pharmacological effects, such as the improvement of allergic diseases, when the composition of the present invention is administered to a mammal, preferably a human subject to the application, during the administration period as suggested by a medical professional. It refers to the amount of the active ingredient included in the composition of the present invention. Such an effective amount can be determined empirically within the ordinary ability of one of ordinary skill in the art.

In addition to the active ingredient, the anti-allergic composition of the present invention may further include any compound or natural extract known to have anti-allergic activity and safety has already been verified to increase/reinforce anti-allergic activity.

Specifically, as such a compound or extract, Enterococcus faecalis heat-treated dry powder, which has been individually recognized for its 'alleviating hypersensitivity immune response' function according to the Korean 「Health Functional Food Act」, complexes such as guava leaf extract, Actinidia extract, leaf extract, Composite such as picaopreto powder, PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol), L. sakei Probio 65, which has been individually recognized for its 'improving sensitive skin condition' function, oil containing gamma-linolenic acid , fruit and vegetable-derived lactic acid bacteria ( L. plantarum CJLP133), probiotics ATP, and the like.

One or more of these compounds or natural extracts may be included in the anti-allergic composition of the present invention together with its active ingredient.

In a specific embodiment, the anti-allergic composition of the present invention can be grasped as a food composition. When the composition of the present invention is identified as a food composition, its use may be understood to inhibit allergic skin hypersensitivity reaction.

The food composition of the present invention can be prepared in any form, for example, beverages such as tea, juice, carbonated drinks, and ion drinks, processed oils such as milk and yogurt, gums, rice cakes, Korean sweets, bread, confectionery, noodles, etc. Foods, tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, and health functional food preparations such as bars can be manufactured.

In addition, the food composition of the present invention may have any product classification in terms of legal and functional classification as long as it conforms to the enforcement laws at the time of manufacture and distribution. For example, it is a health functional food according to Korea's "Health Functional Food Act", or confectionery, beans, tea, and beverages according to each food type in the Food Ordinance of Korea "Food Sanitation Act" (Ministry of Food and Drug Safety Notification "Food Standards and Specifications") , special purpose food, and the like.

The food composition of the present invention may contain food additives in addition to the active ingredients thereof. Food additives can be generally understood as substances that are added and mixed or infiltrated into food in manufacturing, processing, or preserving food. Food additives with guaranteed safety are limited in terms of ingredients or functions in the Food Additives Ordinance in accordance with the laws of each country that regulates the manufacture and distribution of food (“Food Sanitation Act” in Korea). In the Korean Food Additives Code (“Food Additive Standards and Specifications” announced by the Ministry of Food and Drug Safety), food additives are classified into chemically synthetic products, natural additives, and mixed preparations in terms of ingredients. It is divided into agents, preservatives, emulsifiers, acidulants, thickeners, etc.

The sweetener is used to impart appropriate sweetness to food, and both natural and synthetic ones may be used in the composition of the present invention. Preferably, a natural sweetener is used. Examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.

Flavoring agents may be used to improve taste or aroma, and both natural and synthetic ones may be used. Preferably, it is a case where a natural thing is used. In the case of using a natural product, the purpose of nutritional enhancement in addition to flavor may be concurrently used. The natural flavoring agent may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, or the like, or obtained from green tea leaves, honeysuckle, bamboo leaves, cinnamon, chrysanthemum leaves, jasmine, and the like. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, and ginkgo can be used. The natural flavoring agent may be a liquid concentrate or a solid extract. Optionally, a synthetic flavoring agent may be used, and the synthetic flavoring agent may be an ester, an alcohol, an aldehyde, a terpene, or the like.

As a preservative, sodium calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. can be used, and as an emulsifier, acacia gum, carboxymethylcellulose, xanthan gum, Pectin, etc. are mentioned, and acidulant, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, etc. can be used as an acidulant. The acidulant may be added so that the food composition has an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to the purpose of enhancing the taste.

As a thickening agent, a suspending agent, a settling agent, a gel former, a bulking agent, etc. can be used.

The food composition of the present invention may contain, in addition to the food additives described above, physiologically active substances or minerals known in the art for the purpose of supplementing and reinforcing functionality and nutrition and guaranteed stability as food additives.

Examples of such physiologically active substances include catechins contained in green tea and the like, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoylthiamine, and the like. Minerals include calcium preparations such as calcium citrate, magnesium stearate Magnesium preparations, such as iron preparations, such as iron citrate, chromium chloride, potassium iodide, selenium, germanium, vanadium, zinc, etc. are mentioned.

In the food composition of the present invention, the food additives as described above may be included in an appropriate amount to achieve the purpose of the addition according to the product type.

In relation to other food additives that may be included in the food composition of the present invention, reference may be made to the Food Ordinance of each country or the Food Additives Code.

The composition of the present invention may be regarded as a pharmaceutical composition in another specific embodiment.

The pharmaceutical composition of the present invention may be prepared as an oral dosage form or a parenteral dosage form according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. Here, the route of administration may be any suitable route including topical route, oral route, intravenous route, intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination. An example of the combination of two or more routes is a case in which two or more formulations of drugs according to the route of administration are combined. For example, one drug is first administered by an intravenous route and the other drug is secondarily administered by a local route.

Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or formulation, and specifically, reference may be made to the pharmacopoeia of each country including the "Korea Pharmacopoeia".

When the pharmaceutical composition of the present invention is prepared as an oral dosage form, powders, granules, tablets, pills, dragees, capsules, liquids, gels, syrups, suspensions, wafers, according to methods known in the art together with a suitable carrier It can be prepared in a formulation such as Examples of suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Cellulose such as hydroxypropylmethylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, glycerol and the like. In the case of formulation, an appropriate binder, lubricant, disintegrant, colorant, diluent, etc. may be included as needed. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweetener, sodium alginate, polyethylene glycol, wax, and the like, and lubricants include sodium oleate. , sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium salt and calcium salt, polyethylene glycol, etc., and as a disintegrant, starch, methyl cellulose, agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt and the like. Examples of the diluent include lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine.

When the pharmaceutical composition of the present invention is prepared for parenteral use, it may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories together with suitable carriers according to methods known in the art. When formulated as an injection, an aqueous isotonic solution or suspension may be used as a suitable carrier, and specifically, PBS (phosphate buffered saline) containing triethanolamine, sterile water for injection, or isotonic solution such as 5% dextrose may be used. . When formulated for transdermal administration, it can be formulated in the form of an ointment, a cream, a lotion, a gel, an external solution, a pasta agent, a liniment agent, an air roll, and the like. In the case of nasal inhalants, it can be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, and the like. witepsol), tween 61, polyethylene glycols, cacao fat, laurin fat, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, sorbitan fatty acid esters, and the like can be used.

Specific formulations of pharmaceutical compositions are known in the art, and reference may be made to, for example, Remington's Pharmaceutical Sciences (19th ed., 1995). This document is considered a part of this specification.

A preferred dosage of the pharmaceutical composition of the present invention is in the range of 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 1 g, depending on the patient's condition, weight, sex, age, severity of the patient, and the route of administration. It can be in the range /kg. Administration may be performed once or divided into several times a day. These dosages should not be construed as limiting the scope of the invention in any respect.

In another specific embodiment, the composition of the present invention can be identified as a cosmetic composition. When the composition of the present invention is identified as a cosmetic composition, its use may be understood as a use for suppressing allergic skin troubles, alleviating allergic skin irritation, and the like.

Even when the composition of the present invention is identified as a cosmetic composition, the cosmetic composition can be classified into any product in terms of its use or by law, and specifically functional cosmetics, non-functional products having uses such as improvement of skin troubles and improvement of atopic dermatitis It may be general cosmetics and the like. In terms of product form, it may take any product form, and specifically, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax It can take the form of products such as foundation and spray. In the specific product form, it may be in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.

The cosmetic composition of the present invention may include components commonly used in cosmetic compositions in addition to the active ingredient, for example, conventional adjuvants such as stabilizers, solubilizers, surfactants, vitamins, pigments and fragrances, and carriers.

When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, specifically water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, etc. may be used.

When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, polyoxyethylene sorbitan ester, microcrystals Adult cellulose, aluminum metahydroxide, bentonite, agar, etc. can be used.

When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide as carrier components Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like may be used.

The cosmetic composition of the present invention can be prepared according to the method for preparing a cosmetic composition conventionally performed in the art, except that it contains the active ingredient exhibiting anti-allergic activity.

As described above, according to the present invention, it is possible to provide a composition for anti-allergy using water-soluble mastic gum or E.

The composition for anti-allergy of the present invention may be commercialized as food, cosmetics, drugs, etc. for the purpose of improving allergic diseases.

1 is a result showing the degranulation inhibitory activity of a mast cell line RBL-2H3 (rat basophilic leukemia) activated with IgE and antigen (DNP-BSA) of a solubilized mastic gum and/or an E. tree extract.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these Examples and Experimental Examples.

<Example> Anti-allergic activity of a mixture of water-soluble mastic gum and E. E. tree extract

1. Preparation of Samples

1.1 Preparation of Soluble Mastic Gum

The mastic gum powder was visually inspected for color confirmation and foreign matter inspection. After that, 20% by weight of the selected mastic gum powder, 75.7% by weight of purified water, 4% by weight of cyclodextrin, and 0.3% by weight of additives (gatti gum) are added, and 30-50° C. It was dispersed so as to have a particle size of about 20-50 μm for 30-60 minutes at 2,000-3,000 rpm. The dispersion of the mastic gum was carried out for 3 to 6 hours using a bead mill (Dentech Co., Ltd.) at 20 to 40° C. so that the final dispersed particles became an average of 600 to 1,000 nm. Then, it was filtered through a 40-60 μm housing filter to obtain an aqueous solution of mastic gum in a suspension state. In the experiment below, this water-soluble mastic gum was used as it is.

1.2 Preparation of E. E. extracts

After extracting the Ecklonia tree (extraction part: leaves, twigs) with 70% alcohol by 4-8 times the weight at 70-85 ° C for 4-8 hours, the filtered filtrate is concentrated under reduced pressure at 60 ° C or less and freeze-dried to form a powder extracts were obtained.

2. Anti-allergic activity test

2.1 Degranulation inhibition activity test using mast cells - β-hexosaminidase assay

Rat mast cells (RBL-2H3, ATCC) were prepared in a 24-well plate at 2.5X10 ⁵ /well, and for allergy induction, anti-DNP IgE (0.5 ug/ml, Sigma-Adrich) was used for 24 hours. cultured. Then, the medium was removed from the 24-well plate that had been cultured the previous day, and after washing by adding 0.5 ml/well of Siraganian buffer, 160 ul of the same buffer was added to each well and reacted in an incubator at 37°C for 10 minutes. After 10 minutes, 20 ul of each sample prepared for each concentration was added and incubated for 10 minutes in an incubator at 37° C., then 20 μl of 10 ug/ml DNP-BSA was added and reacted in an incubator at 37° C. for 30 minutes.

Then, transfer 50 ul of the supernatant from each well to a 96-well plate, add 50 ul of 3 mM PNAG (0.1M citrate buffer, pH 4.5), and react in an incubator at 37° C. for 1 hour. Stop solution (0.1M Na ₂ CO ₃ / NaHCO ₃ , pH 10.0) 200ul each was added to stop color development, and absorbance was measured at 405 nm. Results were calculated as a percentage of the sample untreated group using the measured absorbance and are shown in FIGS. 1 and 2 . As a positive control group, 2 mM Chlorpheniramine Maleate, an approved anti-allergic drug, was used.

Referring to FIGS. 1 and 2 , water-soluble mastic gum and/or E. E. tree extract exhibited anti-allergic activity (degranulation inhibitory activity, β-hexosaminidase release inhibitory activity) in a concentration-dependent manner. In FIG. 2, Complex 1 (Mix#1) is a complex of 0.4 mg/ml E. E. extract and 19,600 ppm solubilized mastic gum, and Complex 2 (Mix #2) is 0.4 mg/ml E. E. extract and 98,000 ppm solubilized. It is a complex of mastic gum.

2.2 Statistical analysis

In the anti-allergic activity experiment, an independent t-test was performed on the results of repeated three times, and a statistical significance test was performed. The p-value was compared between the positive control group or the complex treatment group, and statistical processing was analyzed using the Excel program.

Claims (6)

Contains a mixture of water-soluble mastic gum and E. E. tree extract as an active ingredient,
The water-soluble mastic gum is a suspension in which mastic gum is made into fine particles (average particle diameter in the range of 1 to 999 μm) or nanoparticles (average particle diameter in the range of 1 to 999 nm) and suspended in water, a solvent, for the treatment of allergic diseases Or as a pharmaceutical composition for prophylaxis,
The allergic disease is atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis (allergic dermatitis), allergic contact dermatitis (allergic contact dermatitis) ), and a pharmaceutical composition, characterized in that one selected from the group consisting of allergic keratitis.
According to claim 1,
The Ecklonia tree extract is a pharmaceutical composition, characterized in that the extract obtained by extraction with water, ethanol, or a mixed solvent thereof.
delete Contains a mixture of water-soluble mastic gum and E. E. tree extract as an active ingredient,
The water-soluble mastic gum is a suspension in which the mastic gum is made into fine particles (average particle diameter in the range of 1-999 μm) to nanoparticles (average particle diameter in the range of 1-999 nm) and suspended in water as a solvent,
A food composition for suppressing allergic reactions.
5. The method of claim 4,
The E. E. tree extract is a food composition, characterized in that it is an extract obtained by extraction with water, ethanol, or a mixed solvent thereof.
Contains a mixture of water-soluble mastic gum and E. E. tree extract as an active ingredient,
The water-soluble mastic gum is a suspension in which the mastic gum is made into fine particles (average particle diameter in the range of 1-999 μm) to nanoparticles (average particle diameter in the range of 1-999 nm) and suspended in water as a solvent,
The Ecklonia tree extract is an extract obtained by extraction with water, ethanol, or a mixed solvent thereof,
A cosmetic composition for suppressing allergic skin troubles.

Images